CooperCompanies Strengthens Leadership with New Appointment
CooperCompanies (NASDAQ: COO), a well-respected name in the medical device sector, has announced significant leadership changes. The Board of Directors has appointed Colleen Jay to take over from Robert Weiss as Chair, with her term starting on January 2, 2026. Robert Weiss, who has been an influential figure in the company, will remain on the Board and seek reelection for one last term.
Leadership Transition and Insights
Al White, the President and CEO of CooperCompanies, expressed gratitude for Weiss's contributions, highlighting his industry knowledge and vision that have been pivotal to the company’s success. White shared his enthusiasm about the appointment of Colleen Jay, stating that her extensive experience and proven track record in leading global operations and innovations will greatly benefit the company.
Colleen Jay's Rich Background
Colleen Jay has been with CooperCompanies since 2016, serving diligently on the company’s Board. Before joining Cooper, she had a distinguished career at Procter & Gamble, where she held various leadership positions for over 32 years. Ms. Jay's final role at P&G was as Global Division President, highlighting her expertise in managing and successfully transitioning major business units.
Robert Weiss's Legacy
Robert Weiss has long been a key player at CooperCompanies, having served as CEO for over a decade until his retirement in 2018. Throughout his career, Weiss held pivotal roles including President of CooperVision, as well as COO and CFO, making substantial contributions to laying a solid foundation for future growth.
Strategic Review for Future Growth
In addition to leadership changes, CooperCompanies is embarking on a thorough strategic review designed to explore new avenues for long-term shareholder value. The Board and Management, alongside their advisors, will analyze the company’s operations, corporate structure, and capital allocation strategies to uncover opportunities for improvement and efficiency.
Commitment to Shareholder Value
This strategic initiative stems from CooperCompanies’ commitment to fostering sustainable growth while enhancing shareholder returns. The company plans to optimize its operations, increase market share, and generate robust financial results through disciplined capital management, including a recently announced $2 billion share repurchase program.
About CooperCompanies
CooperCompanies stands out as a reputable global medical device company dedicated to enriching lives. With two distinct business divisions, CooperVision and CooperSurgical, the company provides innovative solutions aimed at improving vision and reproductive health.
CooperVision is a major player in the contact lens industry, enhancing the daily experiences of its users, while CooperSurgical focuses on supporting women's health and fertility. Headquartered in San Ramon, California, the firm employs over 15,000 people globally and sells its products in over 130 countries, positively influencing millions of lives every year.
Contact Information
For further inquiries, please contact Kim Duncan, Vice President of Investor Relations and Risk Management, at 925-460-3663 or via email at ir@cooperco.com.
Frequently Asked Questions
Who has been appointed as the new Chair of CooperCompanies?
Colleen Jay has been appointed to succeed Robert Weiss as the new Chair of CooperCompanies.
When does the new Chair begin their term?
The new Chair, Colleen Jay, will officially start her term on January 2, 2026.
What is the purpose of the strategic review conducted by CooperCompanies?
The strategic review aims to identify opportunities for improving long-term shareholder value and optimizing business operations.
What notable change is CooperCompanies making regarding capital management?
The company has announced a $2 billion share repurchase program as part of its disciplined capital deployment strategy.
How is CooperCompanies positioned in the medical device market?
CooperCompanies is a leading global medical device company with significant contributions in the contact lens and women’s healthcare sectors.
